←
Mirrors of Medicine3,878 posts
Mirrors of Medicine avatar✓

Mirrors of Medicine ✓

@mirrorsmed

Open, multidisciplinary platform facilitating access to unique #CME programmes w/ focus on improving clinical decision making. Both online & offline.

◷ Joined November 2010▧ 1,808 Photos and videos
Mirrors of Medicine avatar
Mirrors of Medicine@mirrorsmed·22h

🚨 73.8% response rate in advanced TNBC: promising early data for pumitamig + nab-paclitaxel. thelancet.com/journals/lanon… Activity and safety of first-line pumitamig plus nab-paclitaxel in triple-negative breast cancer: a single-arm, phase 1b/2 trial In this phase 1b/2 trial, first-line pumitamig, an investigational PD-L1/VEGF-A bispecific antibody, plus nab-paclitaxel demonstrated encouraging activity in 42 patients with advanced or metastatic triple-negative #BreastCancer . ➡️ At 35.2 months’ median follow-up, the confirmed objective response rate was 73.8%, including one complete response. ➡️ Grade ≥3 toxicities included neutropenia, leukopenia, proteinuria, and febrile neutropenia. No treatment-related deaths occurred. ✅These findings support further evaluation in larger global trials.

Post attachment
Mirrors of Medicine avatar
Mirrors of Medicine@mirrorsmed·Nov 16

Can ctDNA tell us who should get SBRT for oligoprogressive mCRPC? jamanetwork.com/journals/jam… Circulating Tumor DNA in Oligoprogressive Prostate Cancer Treated With Stereotactic Radiotherapy A Prespecified Secondary Analysis of a Nonrandomized Clinical Trial In this prespecified analysis of the phase 2 TRAP trial, 77 patients with oligoprogressive metastatic castration-resistant #ProstateCancer received SBRT while continuing an androgen receptor pathway inhibitor. ➡️Pre-SBRT ctDNA positivity was associated with significantly shorter progression-free survival: median 3.0 vs 7.8 months for ctDNA-negative patients. ✅These findings suggest ctDNA status may help identify patients most likely to benefit from SBRT while continuing ARPI therapy. @f_orlando_, @Dr_AJC, @nickva1, @y_suhughes, @FrancescaBZNY, @alison_tree, @AttardLab

Post attachment
Mirrors of Medicine avatar
Mirrors of Medicine@mirrorsmed·Nov 16

The treatment landscape for high-risk prostate cancer continues to evolve. Following the presentation of the DASL-HiCaP data at #ESMO26, darolutamide provides an additional treatment option to consider. But what would you choose for a patient with newly diagnosed PCa and high-risk features? 👉️ Cast your vote and watch Dr. Tamim niazi discuss the case: ppcp.mirrorsmed.org/en/singl…

Post attachment
Mirrors of Medicine avatar
Mirrors of Medicine@mirrorsmed·Nov 13

🌍 73 UTUC experts. 40 clinical questions. 80% consensus. What should standard practice look like in non-metastatic UTUC? nature.com/articles/s41585-0… International multidisciplinary Delphi consensus on advanced practice in non-metastatic upper tract urothelial carcinoma (IMPACT UTUC) The IMPACT UTUC international Delphi consensus provides expert guidance for non-metastatic upper tract urothelial carcinoma (UTUC), addressing persistent variability in diagnosis, staging, and treatment. ➡️ Seventy-three multidisciplinary experts from Europe, the Americas, and Asia evaluated 40 statements across two rounds. Consensus was reached for 32 statements (80%). ➡️ These recommendations offer a practical, internationally informed framework for current clinical practice and identify areas where prospective evidence remains urgently needed. #BladderCancer @PandolfoSD, @RobertoContieri, @pcvblack, @uretericbud, @danieleamparore, @aleantonellibs1, @RicBertolo, @AlbertoBreda1, @agallioli, @Albert0Briganti, @UroMoschini, @saumyg, @GuidoGiusti, @paolo_gontero, @gonzomdphd, @PGrivasMDPhD, @UroDocAsh, @UrogerliMD, @Dr_Jen_Linehan, @ParamMariappan, @MehrazinMD, @LAUrology_NL, @minerviniandre, @andreamari08, @AndreaNecchi, @montypal , @JamesPorterMD, @BenjaminPradere, @spsutkaMD, @urojdr, @MRoupret, @DrShariat, @nirmishsingla, @endouro, @sonpavde, @cnsternberg, @mdstifelman, @jteoh_hk, @homizargar, @rebeccampbell50, @MariaJRibal, @LiMingSu1, @shilpaonc, @LauraBukavinaMD, @Hoomandjaladat, @Cold_Steel_1970, @ricautor, @Ric_Campi

Post attachment
Mirrors of Medicine avatar
Mirrors of Medicine@mirrorsmed·Nov 12

🚨 Metastatic breast cancer guidelines have changed—across every major subtype. clinical-breast-cancer.com/a… 2026 Key European 🇪🇺 Guideline Changes for Metastatic Breast Cancer and Their Impact on Practice—Commentary Based on a Virtual Focus Group The 2026 @myESMO Living Guidelines update introduces major changes across metastatic #BreastCancer . ➡️ HR-positive/HER2-negative disease now differentiates endocrine-sensitive from endocrine-resistant tumors, with mandatory PIK3CA testing in resistant disease and expanded targeted options. ➡️Trastuzumab deruxtecan 🧪 plus pertuzumab becomes a first-line option in HER2-positive disease, while ADCs move into first-line treatment for #TNBC regardless of PD-L1 status. Implementation will require broader biomarker testing, multidisciplinary toxicity management, and healthcare-team education. @curijoey, @LuisCB_MedPharm, @volkmar_mueller, @Prof_Nadia_H

Post attachment
Mirrors of Medicine avatar
Mirrors of Medicine@mirrorsmed·Nov 11

HER2-positive breast cancer has come a remarkably long way — but the next challenge may be just as important as the breakthroughs that got us here: nature.com/articles/s41571-0… Right-sizing treatment for HER2-positive breast cancer: evolving algorithms across the disease continuum (Review) HER2-positive 🧬 #BreastCancer has been transformed from an aggressive disease into a highly treatable, often curable cancer through advances in targeted therapy. The focus is now shifting from a one-size-fits-all approach toward “right-sized” treatment based on risk, biology, response and patient preferences. Trastuzumab deruxtecan 🧪 is moving into earlier treatment settings, while biomarkers and emerging maintenance strategies may further refine therapy. Key challenges remain around treatment intensity, sequencing, duration and retreatment across the disease continuum. @PTarantinoMD @ValenzaCarmine @elia_segui @nlinmd @prataleix @curijoey @adawaksmd @stolaney1 @OncoAlert 🚨

Post attachment
Mirrors of Medicine avatar
Mirrors of Medicine@mirrorsmed·Nov 10

Can we safely shorten postmastectomy radiation without compromising breast reconstruction outcomes? This randomized trial suggests we can. ovid.com/jnls/ascojco/abstra… Randomized Trial of Hypofractionated Postmastectomy Radiation Therapy in Women With Breast Reconstruction (RT CHARM, Alliance A221505) A randomized noninferiority trial evaluated hypofractionated versus conventional postmastectomy radiation therapy ☢️ (PMRT) in 898 women undergoing breast reconstruction. ➡️ At 24 months, reconstruction complications were similar with 16-fraction hypofractionated PMRT (12.3%) and conventional PMRT (10.2%), meeting the prespecified noninferiority margin. Locoregional recurrence, acute toxicity, and late toxicity were also comparable. ✅ These findings support 16-fraction PMRT as a safe, effective alternative to 25-fraction treatment for patients undergoing breast reconstruction after mastectomy. #breastcancer @BHaffty, @KathrynRuddyMD, @AnnPartridgeMD, @DrLisaCarey, @maryam_lustberg, @shanestecklein

Post attachment
Mirrors of Medicine avatar
Mirrors of Medicine@mirrorsmed·Nov 10

The first DASL-HiCaP results are out. What comes next? Following the first results presented at #ESMO26, join Tamim Niazi as he puts the findings into clinical context and explores what they could mean for patients with non-metastatic prostate cancer with high-risk features. We’ll look beyond the headline results to discuss patient selection, treatment decisions and the questions still to be answered. 📅 19 November 2026 | 17:00 CET ▶️ Available on demand thereafter 👉 Register for the webinar: us02web.zoom.us/webinar/regi… #ProstateCancer @niazi_Dr7 @OncoAlert

Post attachment
Mirrors of Medicine avatar
Mirrors of Medicine@mirrorsmed·Nov 9

Can strategically alternating a VEGFR TKI with bevacizumab turn treatment breaks into an opportunity rather than a compromise? thelancet.com/journals/lanon… Pazopanib alternating with bevacizumab in patients with metastatic clear-cell renal cell carcinoma naive to treatment: a multicentre, single-arm, phase 1/2 trial A phase 1/2 trial evaluated alternating pazopanib and bevacizumab🧪 in treatment-naive metastatic clear-cell renal cell carcinoma, aiming to improve tolerability while maintaining disease control. ➡️The recommended regimen was pazopanib 800 mg for 28 days followed by bevacizumab 10 mg/kg during the treatment break. ➡️Median progression-free survival reached 24.8 months after 63.7 months’ follow-up, with hypertension and liver enzyme elevations the most common grade 3–4 toxicities. Randomised phase 3 validation is needed #KidneyCancer @Dr_SabyGeorge, @drulkav, @deepak_kilari

Post attachment
Mirrors of Medicine avatar
Mirrors of Medicine@mirrorsmed·Nov 9

🔎 What could the VOLGA results mean for cisplatin-ineligible muscle-invasive bladder cancer? 🎥 In this short video, Dr. @BlancJeremy reviews results from the phase 3 VOLGA trial, presented by Powles et al. at ESMO 2026, evaluating perioperative durvalumab + enfortumab vedotin (EV), with or without tremelimumab, in patients with muscle-invasive bladder cancer who were cisplatin-ineligible or declined cisplatin. 📊 Both investigational regimens significantly improved event-free survival compared with radical cystectomy followed by observation or locally approved adjuvant therapy. Importantly, durvalumab + EV also demonstrated a significant overall survival benefit, while safety findings were consistent with the known profiles of the individual agents. 💡 These findings support perioperative durvalumab + EV as a promising treatment strategy for patients with muscle-invasive bladder cancer who are unable or unwilling to receive cisplatin-based chemotherapy. 🔗 Explore the full publication: pubmed.ncbi.nlm.nih.gov/4292… #BladderCancer #MIBC #VOLGA #ESMO26 #GUOncology #Immunotherapy

1:40
OncoAlert avatar
⟳ Mirrors of Medicine retweeted
OncoAlert@OncoAlert·Nov 8

Join OncoAlert and our collaborators at @mirrorsmed for the 2026 Global Forum in GU Oncology. REGISTER HERE: gu-global-forum.org/?utm_sou… Here is our friend, Dr. Philippe BARTHÉLÉMY 🇫🇷, to tell us more about this great forum! 📅 December 2–5, 2026 📍 Amsterdam, Netherlands This is an excellent opportunity to learn how to translate the latest advances in oncology into your clinical practice. #Prosca26 #BLADDR25 #RENALC26 @BertrandTOMBAL @Ric_Campi @achoud72 @bkonety @lisapic @Achard_Verane @MichvdHeijden @roodvdb @Zondervan_AUMC @karolien_goffin

0:55
Mirrors of Medicine avatar
Mirrors of Medicine@mirrorsmed·Nov 6

🧬 Does carboplatin belong in standard neoadjuvant treatment for TNBC—or are we ready to move toward a more biomarker-driven approach? ascopubs.org/doi/full/10.120… Impact of Neoadjuvant Carboplatin in Early-Stage Triple-Negative Breast Cancer: A Pooled Analysis of the BrighTNess, Cancer and Leukemia Group B 40603 (Alliance), and GeparSixto Clinical Trials A pooled analysis of 1,084 patients with early-stage triple-negative #BreastCancer found that adding carboplatin 🧪to anthracycline- and taxane-based neoadjuvant chemotherapy significantly increased pathologic complete response rates and improved event-free survival, although overall survival was not significantly improved. ➡️ Patients with germline 🧬 BRCA mutations also experienced an EFS benefit. ➡️ Immune-related gene signatures were associated with better outcomes, highlighting the importance of the tumor immune microenvironment in TNBC treatment response. @stolaney1, @DrLisaCarey, @hoperugo, @StoverLab, @BCJoyceO, @Metzger_Filho, @LoiblSibylle

Post attachment
Mirrors of Medicine avatar
Mirrors of Medicine@mirrorsmed·Nov 6

Could radiotherapy have a greater role in SMARCB1-deficient renal medullary carcinoma? 🎥 In this short video, Dr. Giovanna Pecoraro (@giovanna55701) highlights findings from the largest reported series of metastasis-directed radiotherapy in RMC. 📊 Radiographic response reached 82%, including 50% complete responses, with 91.3% local control at 12 months. These findings suggest potential radiosensitivity and support further evaluation of radiotherapy in multimodal treatment strategies. 📖 Read the full publication: pubmed.ncbi.nlm.nih.gov/4290… #RenalMedullaryCarcinoma #Radiotherapy #RMC

1:08
Mirrors of Medicine avatar
Mirrors of Medicine@mirrorsmed·Nov 5

📊 When OS improves numerically but statistical significance isn’t reached, how should clinicians interpret the totality of evidence? annalsofoncology.org/article… Overall survival from the phase III postMONARCH trial of abemaciclib plus fulvestrant versus placebo plus fulvestrant for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy PostMONARCH 🦋 reports numerically longer overall survival with abemaciclib plus fulvestrant versus fulvestrant alone in HR+, HER2− advanced #BreastCancer after progression on prior CDK4/6 inhibitor and endocrine therapy 💊 . ➡️ Median OS was 32.1 versus 24.6 months (HR 0.80; 95% CI 0.60–1.06), although statistical significance was not reached. ➡️ Updated PFS, time to second progression, and chemotherapy-free survival also favored abemaciclib, with no new safety signals. @KalinskyKevin, @ErikaHamilton9, @DrSGraff, @RMJesel, @drumutdemirci, @drsarahsam, @BianchiniGP

Post attachment